Author

X. Morelli

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 3 Biophysics· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Organism:human· 3 Assay:bulk RNA-seq· 2 Approach:deep learning· 2 Approach:experimental assay· 2 Approach:statistical model· 2 Approach:biophysical modeling· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

E. Pasquier· 3 shared L. Hoffer· 3 shared S. Betzi· 3 shared Y. Collette· 3 shared A. Restouin· 2 shared C. Derviaux· 2 shared J. Ariey-Bonnet· 2 shared K. Carrasco· 2 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersPharmacology & Toxicology

E. Pasquier

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms

J. Ariey-Bonnet, R. Berges, M.-P. Montero, B. Mouysset, P. Piris, K. Muller, G. Pinna, T. W. Failes, G. M. Arndt, N. Baeza-Kallee, C. Colin, O. Chinot, D. Braguer, X. Morelli, N. ANDRE, , E. Pasquier

This study identifies synergistic drug combinations for glioblastoma by screening core vulnerabilities and validating them in preclinical models.

bioRxiv · Dec 14, 2022Pharmacology & Toxicology

CRCM5484: A BET- BDII Selective Compound With Differential Anti-Leukemic Drug Modulation

K. Carrasco, C. Montersino, C. Derviaux, M. Saez-Ayala, L. Hoffer, A. Restouin, R. Castellano, J. Casassa, P. Roche, E. Pasquier, S. Combes, X. Morelli, Y. Collette, S. Betzi

The paper identifies CRCM5484, a BDII-selective BET inhibitor, and shows its differential modulation of anti-leukemic drug activity in combination with other compounds.

bioRxiv · Dec 13, 2021Cancer Biology

Discovery of small molecule inhibitors of the PTK7/β-catenin interaction targeting the Wnt signaling pathway in colorectal cancer

L. Ganier, S. Betzi, C. Derviaux, P. Roche, C. Muller, L. Hoffer, X. Morelli, J.-P. Borg

This study identifies small molecule inhibitors of the PTK7/β-catenin interaction in colorectal cancer, showing anti-proliferative effects in cells with Wnt pathway mutations.

bioRxiv · Oct 15, 2021 · PreprintPharmacology & Toxicology

Synergy and allostery in ligand binding by HIV-1 Nef

A. Aldehaiman, A. A. Momin, A. Restouin, L. Wang, X. Shi, S. Aljedani, S. Opi, A. Lugari, U. F. S. Hameed, L. Ponchon, X. Morelli, M. Huang, C. Dumas, Y. Collette, S. T. Arold

This study investigates how HIV-1 Nef's flexible regions interact with its core domain to influence SH3 domain selectivity and identifies few human proteins with similar binding properties.

bioRxiv · Nov 5, 2020Biophysics

In silico molecular target prediction unveils mebendazole as a potent MAPK14 inhibitor

J. Ariey-Bonnet, K. Carrasco, M. Le Grand, L. Hoffer, S. Betzi, M. Feracci, P. Tsvetkov, F. Devred, Y. Collette, X. Morelli, P. Ballester, E. Pasquier

This paper identifies mebendazole as a potent MAPK14 inhibitor through in silico target prediction and experimental validation, revealing its potential for repurposing in brain tumor treatment.

bioRxiv · May 18, 2020Pharmacology & Toxicology